UCSF researchers report a new spatial repellent that provides up to one year of protection against malaria and other mosquito-borne diseases, marking the first WHO-endorsed vector control tool in over four decades.
Patients will benefit from significant government investment in new NHS technology to improve treatment, diagnosis and care options for diseases including cancer.
Dr Elizabeth Robertson, Director of Research at Diabetes UK details the hunt for an alternative to century-old Type 1 diabetes treatment – and looks at how British diabetes research is demanding something better.
NHS England will fund treatment for thousands of people with severe Haemophilia, which will lessen the risk of life-threatening Haemophilia bleeds and reduce treatment time.
Research from the Nuffield Department of Population Health, University of Oxford, supported by Diabetes UK, has shown that helping people with Type 2 diabetes to meet their three treatment targets could lead to significant savings for the NHS.
Chief Executive of Brain Tumour Research, Sue Farrington Smith MBE, outlines the priorities for research into brain tumours and why it is imperative we overcome this uniquely devastating cancer.
Prof Dr Regina Fluhrer, from the University of Augsburg, explains how intramembrane proteases have been implicated in the emergence of neurodegenerative diseases.
Diabetes UK has appointed twenty healthcare professionals, including consultants, nurses, GPs, dietitians, podiatrists, pharmacists and psychologists as its newest cohort of Clinical Champions.
The Technical University of Munich (TUM) have published an initial study into how AI robot therapists could be used in the future to treat mental illness: Here we examine their ethical concerns.
Scientists at The University of Manchester are developing a smartphone application connected to goggles which flashlight at a special frequency to use brainwaves to treat pain.
False positives in cancer diagnosis cost NHS millions each year and cause huge anxiety across the nation, Wesley Baker, CEO of ANCON Medical discusses the impact of outdated cancer diagnosis.
